LEADER 05460nam  2200649Ia 450 
001 9910963394703321
005 20251116181443.0
010   $a1-61761-958-2
035   $a(CKB)2550000001040598
035   $a(EBL)3017722
035   $a(SSID)ssj0000826684
035   $a(PQKBManifestationID)12338724
035   $a(PQKBTitleCode)TC0000826684
035   $a(PQKBWorkID)10819476
035   $a(PQKB)11751357
035   $a(MiAaPQ)EBC3017722
035   $a(Au-PeEL)EBL3017722
035   $a(CaPaEBR)ebr10654693
035   $a(OCoLC)923653453
035   $a(BIP)28728249
035   $a(EXLCZ)992550000001040598
100   $a20091229d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCongestive heart failure $esymptoms, causes and treatment /$fJosias E. Garcia and Victoro R. Wright, editors
205   $a1st ed.
210   $aNew York $cNova Science Publishers$dc2010
215   $a1 online resource (244 p.)
225 1 $aCardiology research and clinical developments
300   $aDescription based upon print version of record.
311 08$a1-60876-677-2 
320   $aIncludes bibliographical references and index.
327   $a""CONGESTIVE HEART FAILURE: SYMPTOMS, CAUSES AND TREATMENT""; ""CONGESTIVE HEART FAILURE: SYMPTOMS, CAUSES AND TREATMENT""; ""CONTENTS""; ""PREFACE""; ""MONITORING PULMONARY EDEMA IN CHF PATIENTS WITH A HYBRID BIO-IMPEDANCE APPROACH""; ""ABSTRACT""; ""1. PULMONARY EDEMA IN CHF PATIENTS a??? ORIGINS AND MEASURING TECHNIQUES""; ""2. THE BIO-IMPEDANCE APPROACH IN MEASURING PULMONARY EDEMA""; ""3. A HYBRID BIO-IMPEDANCE SYSTEM FOR DIAGNOSING AND MONITORING CHF PATIENTS""; ""3.1. Technical Design""; ""3.1.1. Hardware design""; ""3.1.2. Software design""; ""Lung resistivity estimation""
327   $a""RR and QT interval calculation""""3.2. Clinical Results""; ""3.2.1. Baseline measurements""; ""3.2.2. CHF patientsa??? classification and long-term monitoring""; ""3.2.3. Monitoring CHF patients under intravenous diuretics treatment""; ""3.2.4. Correlation between bio-impedance measurements and X-ray radiographs""; ""3.3. Monitoring CHF Patients at Home Via a Telemedicine Approach""; ""4. SUMMARY AND CONCLUSIONS""; ""REFERENCES""; ""THE ASSOCIATION BETWEEN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SHOCKS AND HEART FAILURE: A REVIEW OF PATHOGENESIS AND MANAGEMENT""; ""ABSTRACT""
327   $a""1. MADIT II AND SCD-HEFT: TWO MAJOR RANDOMIZED CONTROLLED TRIALS OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY""""2. PATHOGENESIS OF HEART FAILURE IN PATIENTS WITH ICD SHOCKS""; ""The Effect of Shock: Appropriate and Inappropriate Shocks""; ""ICD Shocks and the Activation of Sympathetic Nervous System""; ""The Activation of Sympathetic Nervous System and the Psychiatric Consequences: Impact on Heart Failure Progression""; ""MANAGEMENT""; ""Patient Selection""; ""Optimal Medical Management of Heart Failure""; ""Device Programming""; ""Anti-Arrhythmic Medications, Including Amiodarone""
327   $a""Management of Psychiatric Symptoms and Syndromes""""Organized Protocol for Review of Patients Receiving ICD Shocks""; ""CONCLUSION""; ""REFERENCES""; ""REVERSIBLE LEFT VENTRICULAR DYSFUNCTION: THE TAKOTSUBO SYNDROME""; ""ABSTRACT""; ""INTRODUCTION""; ""Epidemiology""; ""Aetiology""; ""Clinical Features""; ""Diagnosis""; ""Laboratory Data""; ""Cardiac Biomarkers""; ""Stress Hormones""; ""Electrocardiography""; ""Echocardiography""; ""Coronary Angiography and Ventriculography""; ""Cardiovascular magnetic resonance imaging""; ""Myocardial Single Photon Emission Computed Tomography""
327   $a""Endomyocardial Biopsies""""Pathophysiological Mechanisms""; ""Multivessel Epicardial Coronary Artery Spasm""; ""Coronary Microvascular Impairment""; ""Catecholamine Cardiotoxicity""; ""Therepeutic Options""; ""Prognosis""; ""CONCLUSION""; ""REFERENCES""; ""OXIDATIVE STRESS AND HEART FAILURE: STILL A VIABLE THERAPEUTIC TARGET?""; ""ABSTRACT""; ""INTRODUCTION""; ""SOURCES OF OXIDATIVE STRESS IN HEART FAILURE""; ""PHYSIOLOGICAL IMPORTANCE OF REDOX SIGNALING""; ""IMPLICATIONS FOR STEM CELL THERAPY""; ""REDOX-SMART DRUG DESIGN FOR HEART FAILURE""; ""CONCLUSION AND PERSPECTIVES""
327   $a""ACKNOWLEDGEMENT""
330   $aCongestive heart failure (CHF) is a disease that originates from an inadequacy of the heart to maintain blood circulation, resulting in congestion and edema in the body tissues. CHF affects about five million patients in the US alone and an estimated 23 million patients worldwide, and is the only cardiac disease that is growing in prevalence, due to both increasing survival rates of myocardial infarctions and ageing population. In this book, the authors aim to uncover the many hormonal influences on myocardial function and discuss possible aetiological mechanisms, diagnostic modalities and management strategies of the Takotsubo syndrome.
410  0$aCardiology research and clinical developments series.
606   $aCongestive heart failure
606   $aHeart failure
615  0$aCongestive heart failure.
615  0$aHeart failure.
676   $a616.1/29
701   $aGarcia$b Josias E$01868779
701   $aWright$b Victoro R$01868780
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910963394703321
996   $aCongestive heart failure$94476789
997   $aUNINA